GLPwatch
A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus
NCT00642538 · Completed
Last updated 2026-05-28This clinical trial tests the safety and effects of an inhaled powder called MKC253 in adults with type 2 diabetes to see how it influences blood sugar levels after a meal.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 20 people
Who can join Ages 18–70 · all sexes Healthy volunteers accepted.
Timeline Started 2008-02 · est. completion 2008-09
Where 1 site · Netherlands
What this study is testing ClinicalTrials.gov NCT00642538 ↗
Description as written by the study sponsor.
20 eligible subjects will be enrolled into the treatment phase of the trial.
Treatments tested
- MKC253 Inhalation Powder Drug
Inhalation Powder, prandial
- Technosphere Inhalation Powder Drug
Inhalation Powder, prandial
- subcutaneous injection Drug
10µg Exenatide, prandial
| Main thing measured | AUC 0-240 min post-prandial serum glucose |
|---|---|
| Sponsor | Mannkind Corporation |
| Conditions studied | Diabetes Mellitus, Type 2 |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00642538 ↗